Home » Topics » Conferences

Conferences
RSS

Zambon selects a dopaminergic compound for evaluation in cardiovascular/renal disorders

Sep. 6, 1996

Orally active dual NK1/NK2 antagonist from Merck & Co.

Sep. 6, 1996

New adenosine A3 receptor antagonist reported at ACS

Sep. 6, 1996

Potential new treatment for Alzheimer's disease disclosed by SIBIA Neurosciences

Sep. 6, 1996

Reversible MAO inhibitors from Hoechst Marion Roussel

Sep. 6, 1996

A new CETP inhibitor from Schering-Plough

Sep. 6, 1996

alpha1-Adrenoceptor antagonist effective in suppressing prostate cancer growth

Sep. 6, 1996

Abbott evaluating clitocine analogues

Sep. 6, 1996

Abbott describes immunosuppressants

Sep. 6, 1996

HIV protease inhibitor under evaluation at Pharmacia & Upjohn

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 27, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
Abbvie and Simcere enter a $1B T-cell engager deal
BioWorld Asia
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...